This segment focuses on the research and development of novel therapies for neurological disorders, leveraging both small molecule compounds and human neuronal stem cell technology. Research and development activities include preclinical studies, clinical trials, and the identification of new therapeutic targets within the nervous system. The company's lead product candidates, NSI-189 and NSI-566, are being evaluated in clinical trials for major depressive disorder, amyotrophic lateral sclerosis (ALS), and chronic ischemic stroke. The segment utilizes advanced methodologies for isolating and expanding human neural stem cells, enabling the generation of various neuron types. Patient impact is addressed by aiming to provide effective treatments for conditions with high unmet medical needs. Market positioning is based on the development of innovative therapies for neurological diseases. Future opportunities include expanding the pipeline with new drug candidates and exploring partnerships to accelerate clinical development. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials in compliance with regulatory standards. Collaborations with research institutions and pharmaceutical companies are pursued to enhance research capabilities and expand market reach.